Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gloomy Neuroscience Partnering Outlook May Soon Brighten

Executive Summary

At least two companies in the neuroscience space are set to deliver potentially good news by year’s end, with other promising candidates in the offing, according to industry consultant Harry Tracy, who compiled a list of the top 10 partnering opportunities in the field for the upcoming Therapeutic Area Partnerships meeting.

You may also be interested in...



Supernus Set To Launch Trokendi XR Against Generic Topamax

The Maryland CNS company got an FDA approval for its second epilepsy product and will begin marketing the drug before the close of the third quarter.

Mad Scientists And Skunkworks Could Bring Back CNS Creativity, TAP Panelists Say

“Everything that applies to pharma in general is magnified in neuroscience because the timelines are compressed and the punishment for failure is greater,” industry consultant Harry Tracy said at the Therapeutic Area Partnerships meeting.

J&J’s New Innovation Centers Test Immersion Theory Of Access

Johnson & Johnson executives including Pharma Chairman and CSO Paul Stoffels explain how building a presence in innovation’s backyard will allow the health care giant to more easily and quickly access new assets and technologies. Can proximity to innovation make J&J more innovative?

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel